305 related articles for article (PubMed ID: 31861499)
21. The methyltransferase domain of DNMT1 is an essential domain in acute myeloid leukemia independent of DNMT3A mutation.
Bhogal B; Weir BA; Crescenzo R; Marien A; Kwon MC; Philippar U; Cowley GS
Commun Biol; 2022 Nov; 5(1):1174. PubMed ID: 36329185
[TBL] [Abstract][Full Text] [Related]
22. A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells.
Kim SJ; Zhao H; Hardikar S; Singh AK; Goodell MA; Chen T
Blood; 2013 Dec; 122(25):4086-9. PubMed ID: 24167195
[TBL] [Abstract][Full Text] [Related]
23. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.
Walter MJ; Ding L; Shen D; Shao J; Grillot M; McLellan M; Fulton R; Schmidt H; Kalicki-Veizer J; O'Laughlin M; Kandoth C; Baty J; Westervelt P; DiPersio JF; Mardis ER; Wilson RK; Ley TJ; Graubert TA
Leukemia; 2011 Jul; 25(7):1153-8. PubMed ID: 21415852
[TBL] [Abstract][Full Text] [Related]
24. Biologico-clinical significance of DNMT3A variants expression in acute myeloid leukemia.
Lin N; Fu W; Zhao C; Li B; Yan X; Li Y
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):270-277. PubMed ID: 29024628
[TBL] [Abstract][Full Text] [Related]
25. DNMT3L stimulates the DNA methylation activity of Dnmt3a and Dnmt3b through a direct interaction.
Suetake I; Shinozaki F; Miyagawa J; Takeshima H; Tajima S
J Biol Chem; 2004 Jun; 279(26):27816-23. PubMed ID: 15105426
[TBL] [Abstract][Full Text] [Related]
26. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
[TBL] [Abstract][Full Text] [Related]
27. Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia.
Ponciano-Gómez A; Martínez-Tovar A; Vela-Ojeda J; Olarte-Carrillo I; Centeno-Cruz F; Garrido E
Tumour Biol; 2017 Oct; 39(10):1010428317732181. PubMed ID: 28992762
[TBL] [Abstract][Full Text] [Related]
28. DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.
Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
Cell Commun Signal; 2022 Oct; 20(1):168. PubMed ID: 36303144
[TBL] [Abstract][Full Text] [Related]
29. Study on the Immune Escape Mechanism of Acute Myeloid Leukemia With DNMT3A Mutation.
Que Y; Li H; Lin L; Zhu X; Xiao M; Wang Y; Zhu L; Li D
Front Immunol; 2021; 12():653030. PubMed ID: 34093541
[TBL] [Abstract][Full Text] [Related]
30. DNA methylation and hydroxymethylation patterns in acute myeloid leukemia patients with mutations in DNMT3A and IDH1/2 and their combinations.
Šestáková Š; Krejčík Z; Folta A; Cerovská E; Šálek C; Merkerová MD; Pecherková P; Ráčil Z; Mayer J; Cetkovský P; Remešová H
Cancer Biomark; 2019; 25(1):43-51. PubMed ID: 30988238
[TBL] [Abstract][Full Text] [Related]
31. DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia.
Ferreira HJ; Heyn H; Vizoso M; Moutinho C; Vidal E; Gomez A; Martínez-Cardús A; Simó-Riudalbas L; Moran S; Jost E; Esteller M
Oncogene; 2016 Jun; 35(23):3079-82. PubMed ID: 26434589
[TBL] [Abstract][Full Text] [Related]
32. Structure-guided functional suppression of AML-associated DNMT3A hotspot mutations.
Lu J; Guo Y; Yin J; Chen J; Wang Y; Wang GG; Song J
Nat Commun; 2024 Apr; 15(1):3111. PubMed ID: 38600075
[TBL] [Abstract][Full Text] [Related]
33. Mouse DNA methyltransferase (MTase) deletion mutants that retain the catalytic domain display neither de novo nor maintenance methylation activity in vivo.
Zimmermann C; Guhl E; Graessmann A
Biol Chem; 1997 May; 378(5):393-405. PubMed ID: 9191026
[TBL] [Abstract][Full Text] [Related]
34. DNMT3A mutations in acute myeloid leukemia.
Shah MY; Licht JD
Nat Genet; 2011 Mar; 43(4):289-90. PubMed ID: 21445072
[TBL] [Abstract][Full Text] [Related]
35. Conditional knockin of Dnmt3a R878H initiates acute myeloid leukemia with mTOR pathway involvement.
Dai YJ; Wang YY; Huang JY; Xia L; Shi XD; Xu J; Lu J; Su XB; Yang Y; Zhang WN; Wang PP; Wu SF; Huang T; Mi JQ; Han ZG; Chen Z; Chen SJ
Proc Natl Acad Sci U S A; 2017 May; 114(20):5237-5242. PubMed ID: 28461508
[No Abstract] [Full Text] [Related]
36. DNMT3A R882 mutation is associated with elevated expression of MAFB and M4/M5 immunophenotype of acute myeloid leukemia blasts.
Yang L; Liu Y; Zhu L; Xiao M
Leuk Lymphoma; 2015; 56(10):2914-22. PubMed ID: 25721756
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development.
Lu R; Wang P; Parton T; Zhou Y; Chrysovergis K; Rockowitz S; Chen WY; Abdel-Wahab O; Wade PA; Zheng D; Wang GG
Cancer Cell; 2016 Jul; 30(1):92-107. PubMed ID: 27344947
[TBL] [Abstract][Full Text] [Related]
38. Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia.
Jost E; Lin Q; Weidner CI; Wilop S; Hoffmann M; Walenda T; Schemionek M; Herrmann O; Zenke M; Brümmendorf TH; Koschmieder S; Wagner W
Leukemia; 2014 Jun; 28(6):1227-34. PubMed ID: 24280869
[TBL] [Abstract][Full Text] [Related]
39. Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes.
Qu Y; Lennartsson A; Gaidzik VI; Deneberg S; Karimi M; Bengtzén S; Höglund M; Bullinger L; Döhner K; Lehmann S
Epigenetics; 2014 Aug; 9(8):1108-19. PubMed ID: 24866170
[TBL] [Abstract][Full Text] [Related]
40. Mechanistic Insights into Cytosine-N3 Methylation by DNA Methyltransferase DNMT3A.
Dukatz M; Requena CE; Emperle M; Hajkova P; Sarkies P; Jeltsch A
J Mol Biol; 2019 Aug; 431(17):3139-3145. PubMed ID: 31229457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]